55/100Is PFE-Pfizer a buy?
Friday 10 July 2026
Why now: At around $24.25, the stock is priced like a company in long decline, even as management is guiding to 2026 stability and pointing to growth from launched and acquired products. If Pfizer executes, long-term holders are paid to wait through a high dividend while sentiment is still low.
Upside: Base-case upside is 20% to 35% over 12-24 months if the market re-rates the stock from a single-digit earnings multiple toward a more normal large-pharma range, while the dividend adds meaningful total return. A higher outcome depends on clear evidence that new and acquired products can offset patent and pricing headwinds into 2027.
Risks: The biggest risk is that patent expirations and Medicare-negotiated pricing hit faster than expected, forcing guidance cuts. A second risk is that leadership transition in finance and ongoing pipeline execution fail to rebuild investor trust.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free, no credit card needed.
Scorecard
| Scorecard | 55/100 | |
|---|---|---|
| Company Detail | PFE, Pfizer Inc. | |
| Price as at 9 July 2026 | $24.25 | |
| Market cap | $138.2B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 0/20 | |
| Rev/EPS Momentum /20 | 11/20 | |
| Business Quality /15 | 12/15 | |
| Balance Sheet /15 | 10/15 | |
| Valuation /10 | 9/10 | |
| Industry Relative Strength /10 | 3/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | Cash generative | |
| Revenue YoY | -1.6% | |
| EPS YoY | -3.5% | |
| FCF YoY | -7.7% | |
| Gross margin | 74.3% | |
| Valuation & Trend | ||
| Trailing P/E | 18.4x | |
| Forward P/E | 8.6x | |
| RSI (14d) | 42 | |
| vs 50d SMA | -4.8% | |
| Support cushion | −2.4% | |
| Sentiment | ||
| Wall Street verdict | Aligned | |
| News tone | Negative | |
| Dividend | 7.2% | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3, 2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis, Friday 10 July 2026
Albert Bourla has been Chief Executive Officer since 2019 and also serves as Chairman.
Cecile de Brébisson was named interim Chief Financial Officer in June 2026 after Dave Denton announced he will depart in August 2026.
Receiver of capital expenditure: No, Pfizer is not meaningfully a receiver of customer capital expenditure; demand is driven by healthcare utilization and reimbursement rather than customers building capacity for Pfizer.
Main customers
- Wholesalers and distributors (Large pharmaceutical wholesalers and distributors that supply retail pharmacies and hospitals.)
- Government and public health buyers (Public-sector purchasing can be meaningful for certain vaccines and antiviral categories depending on season and policy.)
- Hospitals and oncology clinics (channel demand) (Provider-administered drugs and oncology products flow through clinical and hospital settings.)
Notable contracts
- Eliquis co-commercialization partnership (with Bristol Myers Squibb) (Pfizer shares economics on Eliquis, a large anticoagulant franchise that faces pricing and exclusivity pressure over time.)
- Padcev collaboration (with Astellas) (Padcev is part of Pfizer’s oncology growth mix following the Seagen acquisition, with ongoing partnered development and commercialization.)
- Pfizer is a high-cash-flow pharma franchise that is trying to prove it can transition from the COVID-era peak into a steadier, diversified earnings base.
- The long-term ownership case is mainly valuation plus cash return: the stock is cheap versus peers and pays a very large dividend while the company works through a known patent and pricing schedule.
- This is a qualified long-term yes because the chart is weak, but the price already reflects a lot of bad news and 2026 guidance suggests a floor if execution holds.
Show 1 headline from the last 7d
Scores 55 out of 100, a mixed overall grade. Sector fit, valuation, and business quality scored highest. Balance sheet and earnings trend were fair but not standout drivers. Relative strength versus its industry and chart setup weighed on the total. The score is capped because the chart is weak (not in a confirmed uptrend) and the next 2-3 years include meaningful patent and pricing pressure that can keep the stock range-bound even if execution is decent.
Component scores are on the scorecard above.
- The tape is not supportive right now: the stock is down over the last 90 days, the 200-day moving average is not rising, and industry relative strength is weak versus the healthcare sector.
- The small overnight uptick to about $24.25 does not change the longer trend, so this is not a momentum pick; it is a valuation-and-execution pick that needs business proof points to turn the chart.
- Pfizer has guided to 2026 revenues of about $59.5 billion to $62.5 billion and adjusted earnings per share of about $2.80 to $3.00, and it reaffirmed that guidance after reporting first-quarter 2026 results.
- The company is also running a multiyear cost realignment program and has communicated a large net cost savings target through 2026.
- Key red flags are real and should not be ignored: major products face a mix of exclusivity losses and government-set pricing pressure, including Eliquis already under Medicare-negotiated pricing as of January 1, 2026, and additional negotiated prices expected to follow for other products in 2027 and 2028.
- In addition, a CFO transition was announced in June 2026, which can create uncertainty even if the underlying plan is unchanged.
Cash runway: Cash generative (latest annual free cash flow is positive).
Upcoming (1-6 months)
- Next earnings report and any update to 2026 guidance, especially commentary on new and acquired product growth versus exclusivity and pricing pressure.
Ongoing
- Progress in oncology growth (including Seagen-related products) and the company’s ability to keep cost savings on track through 2026 without harming pipeline output.
Risks
- Faster-than-expected erosion in key franchises from exclusivity loss and price negotiation, leading to earnings misses and guidance cuts.
- Pipeline setbacks or weaker-than-expected uptake of newer and acquired products, which would remove the main bridge across the 2026-2030 pressure period.
- Dividend sustainability risk if free cash flow weakens materially during the transition.
Breaks the thesis
- A material cut to 2026 guidance tied to core business weakness (not one-time items), especially if paired with commentary that cash returns must be reduced to protect the balance sheet.